Mankind Pharma settles flat post-Q4 announcement

Mankind Pharma share price: Mankind Pharma Ltd, NSE: MANKIND settled flat on May 31, Wednesday, a day after the pharmaceutical company based in Delhi reported its Q4 earnings. The stock finished at Rs 1,360, up by 0.30 per cent or Rs 4.05 on NSE.

Mankind Pharma Q4 results

The country's fourth-largest pharmaceutical company by domestic sales reported a 50 per cent year-on-year (YOY) rise in Q4 profit helped by lower input costs. Manforce condom maker's net profit climbed to Rs 28,543.86 against Rs 19,007.91 logged in the year-ago period, in the first earnings as a listed company. Topline revenue from operations of the company, which also makes acute and chronic therapeutics including anti-infectives, respiratory and anti-diabetics stood at Rs 205,266.7, a rise of around 19 per cent from Rs 172,576.11 logged a year ago. Input costs for the pharma company fell 23.4 per cent.

Mankind Pharma share price target

Global brokerage firm Macquarie has maintained an outperform on the counter with a target price of Rs 1,400 post Q4 announcement. 

Mankind Pharma made an impressive debut at the bourses on May 9. The stock was listed at a 20 per cent premium to the issue price of Rs 1,080, and it settled the session with over a 30 per cent premium.

Click Here For Latest Updates On Stock Market | Zee Business Live